A5047707907- Coronary Interventions and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Valve Diseases and Treatments
- Peripheral Artery Disease Management
- Lipoproteins and Cardiovascular Health
- Cerebrovascular and Carotid Artery Diseases
- Aortic aneurysm repair treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Cardiovascular Disease and Adiposity
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Health and Disease Prevention
- Cardiac and Coronary Surgery Techniques
- Cardiac Arrhythmias and Treatments
- Vascular Procedures and Complications
- Congenital Heart Disease Studies
- Blood Pressure and Hypertension Studies
- Integrated Circuits and Semiconductor Failure Analysis
- Statistical Methods in Clinical Trials
- Body Composition Measurement Techniques
- Pulmonary Hypertension Research and Treatments
Toho University Ohashi Medical Center
2012-2025
Tokyo Rosai Hospital
2023-2025
Toho University
2012-2025
Fuji Heavy Industries Health Insurance Society Ota Memorial Hospital
2015-2023
Ollscoil na Gaillimhe – University of Galway
2023
European Society of Cardiology
2023
University of Amsterdam
2019-2022
Amsterdam University Medical Centers
2019-2021
Amsterdam UMC Location University of Amsterdam
2018-2021
Amsterdam Neuroscience
2019-2021
There are few reports demonstrating a relationship between carotid artery ultrasound (carotid-US) findings and the complexity of coronary disease. We aimed to examine carotid-US severity SYNTAX score (SXscore). Subjects were 501 consecutive patients who underwent first angiography from December 2008 January 2011. Carotid-US was used determine mean common intima-media thickness (meanIMT) plaque (PS). The prevalences low (0–22), intermediate (23–32), high (≥33) SXscore 84.8, 7.4, 7.8%,...
<h3>Importance</h3> The role of aspirin as part antiplatelet regimens in acute coronary syndromes (ACS) needs to be clarified the context newer potent P2Y12 antagonists. <h3>Objective</h3> To evaluate benefit and risks addition ticagrelor among patients with ACS beyond 1 month after percutaneous intervention (PCI). <h3>Design, Setting, Participants</h3> This is a nonprespecified, post hoc analysis GLOBAL LEADERS, randomized, open-label superiority trial comparing 2 treatment strategies PCI....
To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month aspirin 12-month DAPT) after complex percutaneous coronary intervention (PCI).In present post hoc analysis Global Leaders trial, primary endpoint [composite all-cause death or new Q-wave myocardial infarction (MI)] at 2 years was assessed in patients with PCI, which includes least one characteristics: multivessel ≥3 stents...
<h3>Importance</h3> Women experience worse ischemic and bleeding outcomes after percutaneous coronary intervention (PCI). <h3>Objectives</h3> To assess the association of sex with patient at 2 years contemporary PCI efficacy safety antiplatelet strategies. <h3>Design, Setting, Participants</h3> This study is a prespecified subgroup analysis investigator-initiated, prospective, randomized GLOBAL LEADERS evaluating strategies therapy in an unselected population including 130 secondary/tertiary...
The purpose of the study was to investigate whether favourable outcomes state-of-the-art PCI in SYNTAX II trial, demonstrated at one year, were maintained two-year follow-up.The a multicentre, single-arm that investigated impact contemporary strategy on clinical 454 patients with de novo three-vessel coronary artery disease, without left main disease. Clinical compared predefined (SYNTAX-I PCI) and bypass graft CABG) cohorts from landmark trial (SYNTAX-I), selected basis equipoise for...
P2Y12 inhibitor monotherapy without aspirin immediately after percutaneous coronary intervention (PCI) has not been tested in East Asian patients, so this study we aimed to assess the safety and feasibility of reduced dose (3.75 mg/day) prasugrel Japanese patients presenting with chronic syndrome (CCS).
Vessel-level physiological data derived from pressure wire measurements are one of the important determinant factors in optimal revascularisation strategy for patients with multivessel disease (MVD). However, these may result complications and a prolonged procedure time.
Abstract Objectives To investigate the impact of minimal stent area (MSA) evaluated by post‐procedural intravascular ultrasound (IVUS) on clinical outcomes after contemporary PCI in patients with three‐vessel disease (TVD). Background The MSA has not yet been extensively studied TVD. Methods SYNTAX II study is a multicenter, all‐comers, open‐label, single arm that investigated state‐of‐the‐art strategy TVD (454 1,559 lesions). relationships between and lesion‐level at 2 years were...
The Acetyl Salicylic Elimination Trial (ASET) Japan pilot study is a multicentre, single-arm, open-label, proof-of-concept with stopping rule based on the occurrence of definite stent thrombosis. This aims to demonstrate feasibility and safety low-dose prasugrel monotherapy following percutaneous coronary intervention (PCI) in Japanese patients presenting chronic syndromes (CCS) or non-ST-elevation acute (NSTE-ACS). Four hundred SYNTAX score <23 requiring PCI due CCS NSTE-ACS will be...
The geographical disparity in the pathophysiological pattern of coronary artery disease (CAD) among patients undergoing percutaneous intervention (PCI) is unknown.